JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

Kodu・Aktsiate loetelu・Design Therapeutics Inc

Design Therapeutics Inc

Avatud

9.8 -1.8

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.32

Max

10.15

Põhinäitajad
By Trading Economics
Sissetulek	2.1M -17M
Töötajad	55
EBITDA	4.7M -17M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+44.65% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	9. märts 2026

Turustatistika
By TradingEconomics
Turukapital	220M 593M
Eelmine avamishind	11.6
Eelmine sulgemishind	9.8

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

3.26 / 3.63 Toetus ja vastupanu

Design Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. veebr 2026, 00:00 UTC

Kuumad aktsiad

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4. veebr 2026, 22:55 UTC

Tulu

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4. veebr 2026, 21:44 UTC

Tulu

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4. veebr 2026, 21:39 UTC

Tulu

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5. veebr 2026, 00:00 UTC

Tulu

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5. veebr 2026, 00:00 UTC

Tulu

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4. veebr 2026, 23:45 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4. veebr 2026, 23:32 UTC

Market Talk

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4. veebr 2026, 22:59 UTC

Omandamised, ülevõtmised, äriostud

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4. veebr 2026, 22:30 UTC

Tulu

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4. veebr 2026, 22:30 UTC

Tulu

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4. veebr 2026, 22:21 UTC

Tulu

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4. veebr 2026, 22:17 UTC

Market Talk

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4. veebr 2026, 22:15 UTC

Market Talk

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4. veebr 2026, 22:00 UTC

Market Talk

ESG Roundup: Market Talk

4. veebr 2026, 21:53 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4. veebr 2026, 21:51 UTC

Tulu

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

4. veebr 2026, 21:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

4. veebr 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

4. veebr 2026, 21:45 UTC

Tulu

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4. veebr 2026, 21:44 UTC

Tulu

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4. veebr 2026, 21:43 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4. veebr 2026, 21:41 UTC

Tulu

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4. veebr 2026, 21:36 UTC

Market Talk

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4. veebr 2026, 21:30 UTC

Tulu

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4. veebr 2026, 21:30 UTC

Tulu

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4. veebr 2026, 21:30 UTC

Tulu

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Võrdlus sarnastega

Hinnamuutus

Design Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

44.65% tõus

12 kuu keskmine prognoos

Keskmine 15 USD 44.65%

Kõrge 18 USD

Madal 13 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Design Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Design Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.26 / 3.63Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.